Doctor of Optometry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Cassano

Optometrist Naperville, IL Doctor of Optometry

NPI 1730138801 CMS profile 611661

608 S Washington St, Suite 306, Naperville, IL 60540

Open in the dashboard

General payments

$17,159

140 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Cassano of Naperville, IL is reported in the CMS Open Payments database as having received $17,159 across 140 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Optometrist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,700 15
2024 General $813 21
2023 General $1,479 30
2022 General $465 29
2021 General $2,724 17
2020 General $2,661 12
2019 General $2,317 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Cassano
  • Optometrist median
  • Middle half of Optometrist
  • National median

In program year 2025, general payments to Michael Cassano were reported at $6,700. Among 35,373 Optometrist profiles paid that year, the median was $204 and the middle half received between $87 and $464.

Show as a table
Year Michael Cassano Optometrist median Middle half National median
2019 $2,317 $159 $67–$371 $163
2020 $2,661 $72 $29–$165 $114
2021 $2,724 $125 $46–$292 $132
2022 $465 $162 $66–$374 $149
2023 $1,479 $177 $72–$406 $160
2024 $813 $188 $77–$427 $164
2025 $6,700 $204 $87–$464 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. CooperVision Inc. $11,114 20 payments
  2. Alcon Vision LLC $4,576 33 payments
  3. Johnson & Johnson Vision Care, Inc. $328 18 payments
  4. Oyster Point Pharma, Inc. $269 19 payments
  5. Bausch & Lomb Americas Inc. $249 14 payments
  6. Thea Pharma Inc. $218 13 payments
  7. Novartis Pharmaceuticals Corporation $147 8 payments
  8. Bausch & Lomb, a division of Bausch Health US, LLC $94 6 payments
  9. Allergan Inc. $51 3 payments
  10. Tarsus Pharmaceuticals, Inc. $29 1 payment
  11. Other $84 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $15,150 10 payments
  2. Food and Beverage $2,009 130 payments
Products named General payments · program years 2019–2025
  1. Clariti Contact Lens $5,050 5 payments
  2. MyDay Contact Lens $5,034 4 payments
  3. DAILIES TOTAL1 $3,000 4 payments
  4. DAILIES $1,315 8 payments
  5. Non-Product Brand Specific $900 1 payment
  6. Acuvue $328 18 payments
  7. TYRVAYA $221 16 payments
  8. XIIDRA $181 10 payments
  9. IYUZEH $168 10 payments
  10. TOTAL30 $159 13 payments
  11. Other $1,100 72 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$20,965

Medicare's payments for the services billed

Medicare patients

206

Average age 73

Services billed

3,577

123 women, 83 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 57%
Arthritis 39%
Ischemic heart disease 20%
Osteoporosis 18%
Diabetes 17%
Depression 16%
Chronic kidney disease 15%
Cancer 13%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
IYUZEH
  • Thea Pharma Inc. $81
$81 — —
VEVYE
  • Harrow Eye, LLC $25
$25 — —
TYRVAYA
  • Oyster Point Pharma, Inc. $24
$24 — —
Cequa
  • Sun Pharmaceutical Industries Inc. $16
$16 — —
MIEBO
  • Bausch & Lomb Americas Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

140 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Optometrist in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record